Clinical Trials for Pancreas Cancer

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic solid tumors other than NSCLC that harbor an activating HER2 mutation are eligible after appropriate standard therapy or when no satisfactory alternative exists; prior HER2 tyrosine kinase inhibitor treatment and active brain metastases are excluded. All participants receive oral sevabertinib, a reversible HER2-directed tyrosine kinase inhibitor, 20 mg twice daily.

ClinicalTrials.gov ID: NCT06760819

A Phase II Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced pancreatic adenocarcinoma or adenosquamous carcinoma, pancreatic or gastrointestinal neuroendocrine neoplasms (Ki-67 >20%), or metastatic prostate cancer with neuroendocrine features after progression on or intolerance of standard therapy receive oral ESK981 in separate single-arm cohorts. ESK981 is an investigational kinase inhibitor targeting VEGFR-1, VEGFR-2, and Tie-2, with preclinical evidence of PIKfyve inhibition.

ClinicalTrials.gov ID: NCT05988918

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously treated, progressing, unresectable locally advanced or metastatic well-differentiated grade 1–3 pancreatic or extrapancreatic NETs are randomized to oral zanzalintinib or everolimus; prior VEGFR-targeting tyrosine kinase inhibitors or mTOR inhibitors are excluded. Zanzalintinib is an investigational multikinase inhibitor targeting VEGFR2, MET, TYRO3, AXL, and MER.

ClinicalTrials.gov ID: NCT06943755

A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with microsatellite-stable metastatic pancreatic ductal adenocarcinoma that has progressed after at least one systemic therapy receive SBRT followed by botensilimab, an investigational Fc-engineered anti-CTLA-4 antibody, plus balstilimab, an investigational anti-PD-1 antibody. Eligible patients must have ECOG 0–1 and a previously unirradiated, biopsy-accessible lesion.

ClinicalTrials.gov ID: NCT06843551

A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls patients with metastatic pancreatic ductal adenocarcinoma with homozygous MTAP deletion or tumor MTAP loss who are generally untreated for metastatic disease. It compares nab-paclitaxel and gemcitabine plus BMS-986504, an oral MTA-cooperative PRMT5 inhibitor, with the same chemotherapy plus placebo.

ClinicalTrials.gov ID: NCT07076121

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated metastatic pancreatic adenocarcinoma and ECOG performance status 0–1 receive either oral atebimetinib, an allosteric MEK1/2 inhibitor, plus modified-schedule gemcitabine/nab-paclitaxel or standard-schedule gemcitabine/nab-paclitaxel.

ClinicalTrials.gov ID: NCT07562152

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed metastatic pancreatic adenocarcinoma, ECOG 0–1, and no prior systemic therapy for metastatic disease are randomized to first-line daraxonrasib alone, daraxonrasib plus gemcitabine/nab-paclitaxel, or gemcitabine/nab-paclitaxel alone. Daraxonrasib is an oral RAS(ON) inhibitor that targets active, GTP-bound RAS signaling.

ClinicalTrials.gov ID: NCT07491445

A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic pancreatic ductal adenocarcinoma that has progressed after exactly one prior systemic therapy receive intravenous nuzefatide pevedotin (BT5528) alone. This Bicycle drug conjugate targets EphA2 and delivers the microtubule-disrupting payload MMAE.

ClinicalTrials.gov ID: NCT07450859

A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Carcinomas (NECs)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously treated, progressing, measurable survivin-positive metastatic grade 3 well-differentiated neuroendocrine tumors of gastrointestinal, pancreatic, or thoracic origin, or neuroendocrine carcinoma of any origin except small-cell lung cancer, receive temozolomide plus SurVaxM. SurVaxM is an investigational peptide vaccine designed to elicit immune responses against survivin-expressing tumor cells.

ClinicalTrials.gov ID: NCT06202066

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated metastatic KRAS G12D-mutated pancreatic adenocarcinoma and ECOG 0–1 receive investigator-selected modified FOLFIRINOX or gemcitabine plus nab-paclitaxel, with either oral zoldonrasib or placebo. Zoldonrasib is an investigational inhibitor of active KRAS G12D that forms a complex with cyclophilin A to block downstream signaling.

ClinicalTrials.gov ID: NCT07621718